Report Detail
Global Osteoporosis Drugs Market Growth 2019-2024
- RnM2938421 |
- 13 February, 2019 |
- Global |
- 130 Pages |
- LPI(LP Information) |
- Pharma & Healthcare
Osteoporosis is a disease where decreased bone strength increases the risk of a broken bone. It is the most common reason for a broken bone among the elderly. Bones that commonly break include the back bones, the bones of the forearm, and the hip. Until a broken bone occurs there are typically no symptoms. Bones may weaken to such a degree that a break may occur with minor stress or spontaneously. Chronic pain and a decreased ability to carry out normal activities may occur following a broken bone.
Osteoporosis Drugs is a kind of medicine for Osteoporosis, such as Fosamax, Actonel, Boniva, Zoledronic Acid (Reclast or Zometa) and others.
Osteoporosis, which literally means porous bone, is a disease in which the density and quality of bone are reduced. As bones become more porous and fragile, the risk of fracture is greatly increased. The loss of bone occurs silently and progressively. Often there are no symptoms until the first fracture occurs. Osteoporosis drugs are a kind of medicine for Osteoporosis. The types of osteoporosis drugs mainly include antiresorptive drugs and anabolic drugs.
The Brazil osteoporosis drugs is Very concentrated, the sales of top eight manufacturers account exceeds 70% of Brazil sales.
The antiresorptive drugs is the main types of osteoporosis drugs. In 2015, the sales revenue of antiresorptive drugs is about 109 M USD; its proportion of total osteoporosis drugs exceeds 73%.
According to this study, over the next five years the Osteoporosis Drugs market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Osteoporosis Drugs business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Osteoporosis Drugs market by product type, application, key manufacturers and key regions and countries.
This study considers the Osteoporosis Drugs value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Antiresorptive Drugs
Anabolic Drugs
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Female
Male
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Eli Lilly
Novartis
Pfizer
Amgen
Merck
Novo nordisk
Actavis
Roche
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Osteoporosis Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Osteoporosis Drugs market by identifying its various subsegments.
Focuses on the key global Osteoporosis Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Osteoporosis Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Osteoporosis Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Table of Contents
2019-2024 Global Osteoporosis Drugs Consumption Market Report
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Research Objectives
- 1.3 Years Considered
- 1.4 Market Research Methodology
- 1.5 Economic Indicators
- 1.6 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Osteoporosis Drugs Consumption 2014-2024
- 2.1.2 Osteoporosis Drugs Consumption CAGR by Region
- 2.2 Osteoporosis Drugs Segment by Type
- 2.2.1 Antiresorptive Drugs
- 2.2.2 Anabolic Drugs
- 2.3 Osteoporosis Drugs Consumption by Type
- 2.3.1 Global Osteoporosis Drugs Consumption Market Share by Type (2014-2019)
- 2.3.2 Global Osteoporosis Drugs Revenue and Market Share by Type (2014-2019)
- 2.3.3 Global Osteoporosis Drugs Sale Price by Type (2014-2019)
- 2.4 Osteoporosis Drugs Segment by Application
- 2.4.1 Female
- 2.4.2 Male
- 2.5 Osteoporosis Drugs Consumption by Application
- 2.5.1 Global Osteoporosis Drugs Consumption Market Share by Application (2014-2019)
- 2.5.2 Global Osteoporosis Drugs Value and Market Share by Application (2014-2019)
- 2.5.3 Global Osteoporosis Drugs Sale Price by Application (2014-2019)
3 Global Osteoporosis Drugs by Players
- 3.1 Global Osteoporosis Drugs Sales Market Share by Players
- 3.1.1 Global Osteoporosis Drugs Sales by Players (2017-2019)
- 3.1.2 Global Osteoporosis Drugs Sales Market Share by Players (2017-2019)
- 3.2 Global Osteoporosis Drugs Revenue Market Share by Players
- 3.2.1 Global Osteoporosis Drugs Revenue by Players (2017-2019)
- 3.2.2 Global Osteoporosis Drugs Revenue Market Share by Players (2017-2019)
- 3.3 Global Osteoporosis Drugs Sale Price by Players
- 3.4 Global Osteoporosis Drugs Manufacturing Base Distribution, Sales Area, Product Types by Players
- 3.4.1 Global Osteoporosis Drugs Manufacturing Base Distribution and Sales Area by Players
- 3.4.2 Players Osteoporosis Drugs Products Offered
- 3.5 Market Concentration Rate Analysis
- 3.5.1 Competition Landscape Analysis
- 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion
4 Osteoporosis Drugs by Regions
- 4.1 Osteoporosis Drugs by Regions
- 4.1.1 Global Osteoporosis Drugs Consumption by Regions
- 4.1.2 Global Osteoporosis Drugs Value by Regions
- 4.2 Americas Osteoporosis Drugs Consumption Growth
- 4.3 APAC Osteoporosis Drugs Consumption Growth
- 4.4 Europe Osteoporosis Drugs Consumption Growth
- 4.5 Middle East & Africa Osteoporosis Drugs Consumption Growth
5 Americas
- 5.1 Americas Osteoporosis Drugs Consumption by Countries
- 5.1.1 Americas Osteoporosis Drugs Consumption by Countries (2014-2019)
- 5.1.2 Americas Osteoporosis Drugs Value by Countries (2014-2019)
- 5.2 Americas Osteoporosis Drugs Consumption by Type
- 5.3 Americas Osteoporosis Drugs Consumption by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Key Economic Indicators of Few Americas Countries
6 APAC
- 6.1 APAC Osteoporosis Drugs Consumption by Countries
- 6.1.1 APAC Osteoporosis Drugs Consumption by Countries (2014-2019)
- 6.1.2 APAC Osteoporosis Drugs Value by Countries (2014-2019)
- 6.2 APAC Osteoporosis Drugs Consumption by Type
- 6.3 APAC Osteoporosis Drugs Consumption by Application
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 Key Economic Indicators of Few APAC Countries
7 Europe
- 7.1 Europe Osteoporosis Drugs by Countries
- 7.1.1 Europe Osteoporosis Drugs Consumption by Countries (2014-2019)
- 7.1.2 Europe Osteoporosis Drugs Value by Countries (2014-2019)
- 7.2 Europe Osteoporosis Drugs Consumption by Type
- 7.3 Europe Osteoporosis Drugs Consumption by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 7.9 Spain
- 7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
- 8.1 Middle East & Africa Osteoporosis Drugs by Countries
- 8.1.1 Middle East & Africa Osteoporosis Drugs Consumption by Countries (2014-2019)
- 8.1.2 Middle East & Africa Osteoporosis Drugs Value by Countries (2014-2019)
- 8.2 Middle East & Africa Osteoporosis Drugs Consumption by Type
- 8.3 Middle East & Africa Osteoporosis Drugs Consumption by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers and Impact
- 9.1.1 Growing Demand from Key Regions
- 9.1.2 Growing Demand from Key Applications and Potential Industries
- 9.2 Market Challenges and Impact
- 9.3 Market Trends
10 Marketing, Distributors and Customer
- 10.1 Sales Channel
- 10.1.1 Direct Channels
- 10.1.2 Indirect Channels
- 10.2 Osteoporosis Drugs Distributors
- 10.3 Osteoporosis Drugs Customer
11 Global Osteoporosis Drugs Market Forecast
- 11.1 Global Osteoporosis Drugs Consumption Forecast (2019-2024)
- 11.2 Global Osteoporosis Drugs Forecast by Regions
- 11.2.1 Global Osteoporosis Drugs Forecast by Regions (2019-2024)
- 11.2.2 Global Osteoporosis Drugs Value Forecast by Regions (2019-2024)
- 11.2.3 Americas Consumption Forecast
- 11.2.4 APAC Consumption Forecast
- 11.2.5 Europe Consumption Forecast
- 11.2.6 Middle East & Africa Consumption Forecast
- 11.3 Americas Forecast by Countries
- 11.3.1 United States Market Forecast
- 11.3.2 Canada Market Forecast
- 11.3.3 Mexico Market Forecast
- 11.3.4 Brazil Market Forecast
- 11.4 APAC Forecast by Countries
- 11.4.1 China Market Forecast
- 11.4.2 Japan Market Forecast
- 11.4.3 Korea Market Forecast
- 11.4.4 Southeast Asia Market Forecast
- 11.4.5 India Market Forecast
- 11.4.6 Australia Market Forecast
- 11.5 Europe Forecast by Countries
- 11.5.1 Germany Market Forecast
- 11.5.2 France Market Forecast
- 11.5.3 UK Market Forecast
- 11.5.4 Italy Market Forecast
- 11.5.5 Russia Market Forecast
- 11.5.6 Spain Market Forecast
- 11.6 Middle East & Africa Forecast by Countries
- 11.6.1 Egypt Market Forecast
- 11.6.2 South Africa Market Forecast
- 11.6.3 Israel Market Forecast
- 11.6.4 Turkey Market Forecast
- 11.6.5 GCC Countries Market Forecast
- 11.7 Global Osteoporosis Drugs Forecast by Type
- 11.8 Global Osteoporosis Drugs Forecast by Application
12 Key Players Analysis
- 12.1 Eli Lilly
- 12.1.1 Company Details
- 12.1.2 Osteoporosis Drugs Product Offered
- 12.1.3 Eli Lilly Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.1.4 Main Business Overview
- 12.1.5 Eli Lilly News
- 12.2 Novartis
- 12.2.1 Company Details
- 12.2.2 Osteoporosis Drugs Product Offered
- 12.2.3 Novartis Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.2.4 Main Business Overview
- 12.2.5 Novartis News
- 12.3 Pfizer
- 12.3.1 Company Details
- 12.3.2 Osteoporosis Drugs Product Offered
- 12.3.3 Pfizer Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.3.4 Main Business Overview
- 12.3.5 Pfizer News
- 12.4 Amgen
- 12.4.1 Company Details
- 12.4.2 Osteoporosis Drugs Product Offered
- 12.4.3 Amgen Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.4.4 Main Business Overview
- 12.4.5 Amgen News
- 12.5 Merck
- 12.5.1 Company Details
- 12.5.2 Osteoporosis Drugs Product Offered
- 12.5.3 Merck Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.5.4 Main Business Overview
- 12.5.5 Merck News
- 12.6 Novo nordisk
- 12.6.1 Company Details
- 12.6.2 Osteoporosis Drugs Product Offered
- 12.6.3 Novo nordisk Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.6.4 Main Business Overview
- 12.6.5 Novo nordisk News
- 12.7 Actavis
- 12.7.1 Company Details
- 12.7.2 Osteoporosis Drugs Product Offered
- 12.7.3 Actavis Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.7.4 Main Business Overview
- 12.7.5 Actavis News
- 12.8 Roche
- 12.8.1 Company Details
- 12.8.2 Osteoporosis Drugs Product Offered
- 12.8.3 Roche Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.8.4 Main Business Overview
- 12.8.5 Roche News
13 Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Osteoporosis Drugs . Industry analysis & Market Report on Osteoporosis Drugs is a syndicated market report, published as Global Osteoporosis Drugs Market Growth 2019-2024. It is complete Research Study and Industry Analysis of Osteoporosis Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
